Synta CEO, Safi Bahcall to Speak on Economic Panel at The Atlantic's Live Digital Town Hall on Wednesday, February 9

Digital town hall to discuss job creation and economy of the future

LEXINGTON, Mass., Feb 08, 2011 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Chief Executive Officer, Safi Bahcall, Ph.D. will participate in a panel discussion titled "The View From The Future" on Wednesday, February 9 starting at 11:11 a.m. (ET).

The Atlantic's Live Digital Town Hall is part of a series of events designed to uncover the best ideas on the big issues facing the nation with a focus on how to create the next phase of American economic growth and opportunity. The Washington, D.C. Town Hall is entitled Finding Work, Finding Our Way: Building the Economy and Jobs of the Future and will include leaders from government and the private sector including The Honorable Tim Geithner, Secretary of the Treasury, Mr. Gene Sperling, Director of the National Economic Council, Senator Orrin Hatch, and Mr. Julius Genachowski, Chairman of the Federal Communications Commission.

The event will be streamed live on TheAtlantic.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. For more information, please visit www.syntapharma.com.

SOURCE: Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125